16 December 2021 in Frontiers in Surgery
Background: There are few reports in the literature on the use of Glubran-2 for the embolization of ovarian veins in patients with pelvic venous disorder (PeVD). In addition, a consensus on the efficacy and safety of Glubran-2 has not been reached.Purpose: To investigate the safety and efficacy of ovarian vein embolization (OVE) with N-butyl-2 cyanoacrylate (NBCA) Glubran-2 for the treatment of PeVD.Material and Methods: Between January 2013 and January 2020, 21 women (mean age, 43.9 ± 13.3 years) with PeVD who underwent OVE with Glubran-2 were evaluated. Of those patients, ovarian vein or pelvic venous plexus insufficiency was verified by duplex ultrasound and/or multislice computer tomography (MSCT). The symptoms and signs of PeVD included chronic pelvic pain (CPP) (21/21; 100%), dyspareunia (12/21; 57.1%), dysmenorrhea (10/21; 47.6%), and vulvar varices (3/21; 14.3%). The medical data were retrospectively reviewed.Results: Glubran-2 was employed as the sole embolic material in 18 cases (85.7%) and used to perform rescue embolization in 3 cases (14.3%) due to CPP recurrence 1 month after initial embolization using microcoils. Technically successful embolization was achieved using Glubran-2 in all patients. No Glubran-2 related complications were noted. Neither persistent nor recurrent CPP was observed during follow-up, for which the mean was 62 ± 38 months (range, 12–102 months). Clinical efficacy was evaluated, and all patients exhibited complete or slight improvement of CPP after embolization. The visual analog scale (VAS) score significantly decreased from pre-intervention to post-intervention (p < 0.001). Six patients (28.6%) gave birth to healthy babies during follow-up after embolization with Glubran-2.Conclusions: Ovarian vein embolization with Glubran-2 is a feasible and safe treatment for CPP secondary to PeVD. This treatment may represent a potential and attractive alternative when patients desire symptom relief and want to continue reproducing. Larger studies are warranted to confirm the findings of this study.
1 February 2020 in Quantitative Imaging in Medicine and Surgery
Background: We assessed whether diffusion-weighted imaging (DWI) volume was associated with fluid-attenuated inversion recovery vascular hyperintensities (FVH)-DWI mismatch and functional outcome in patients with acute stroke who received endovascular therapy (EVT). Methods: Fifty-three acute stroke patients who received EVT were enrolled. FVH-DWI mismatch, DWI volume on admission, DWI volume on follow-up, DWI volume growth, the functional outcome at 3 months (mRS) and other clinical data were collected. Receiver operating characteristic (ROC) analysis was performed to evaluate the value of DWI volume in predicting functional outcome after stroke. Results: The FVH-DWI mismatch group had a smaller DWI volume on admission (13.86±19.58 vs. 65.07±52.21; t=−4.301, P=0.000), a smaller DWI volume on follow-up (29.88±33.52 vs. 112.43±87.19; t=−4.143, P=0.000), and a lower DWI volume growth (16.02±19.90 vs. 47.36±40.06; t=−3.326, P=0.003) than those of the no FVH-DWI mismatch group. The good functional outcome group had a smaller DWI volume on admission (13.30±13.26 vs. 68.56±54.28; t=−5.611, P=0.000), a smaller DWI volume on follow-up (27.65±18.80 vs. 120.25±90.37; t=−5.720, P=0.000), lower DWI volume growth (14.35±15.06 vs. 51.69±41.17; t=−4.737, P=0.001) and a higher FVH-DWI mismatch ratio (75.76% vs. 35%; t=8.647; P=0.004) than those of the poor functional outcome group. ROC analysis showed that the sensitivity and specificity of DWI volume on admission for predicting functional outcome were 65% and 96.97%, respectively (the optimal cut-off value: 33.50 mL); DWI volume on follow-up was 48.6 mL, with a sensitivity and specificity of 80% and 87.88%, respectively; DWI volume growth was 22.25 mL, with a sensitivity and specificity of 70% and 87.88%, respectively. Conclusions: DWI volume and DWI volume growth can provide the prognostic information of acute stroke patients after thrombectomy.
21 April 2022 in Annals of Vascular Surgery
24 February 2025 in IEEE Transactions on Instrumentation and Measurement
Objective: The objective of this study is to propose and validate a contact force estimation method based on guider shape prediction, aiming at estimating the contact force between the distal end of the guider and the vascular wall. Methods: A guider prediction algorithm is developed to simulate the stable shape of different contact points within a phantom model. Subsequently, a shape-contact force model is established, and the contact force is estimated based on the parametric equation of the guider shape. A suspended force measuring platform is developed to validate the contact force estimation approach. Additionally, the influence of contact position and guider stiffness on contact force is analyzed. Results: The average accuracy of contact force estimation is 91.17%. The average relative error of the guider shape is 2.5%, with a maximum offset error of 4.6 mm. During the contact force estimation experiment, the maximum relative error of the contact force is 19.83%, and the force deviation is 1.6 × 10-2 N. For Nitinol 0.4 mm at contact point 1, the relative error of the contact force is 11.58%, with a force deviation of 3.0 × 10-3 N. Conclusion: The estimated contact force aligns well with the measured force, demonstrating the feasibility of the proposed contact force estimation method. Significance: This study establishes a sensor-less contact force estimation method for vascular interventional robot guidance systems, offering insights into improving the robot's ability to navigate narrow blood vessels. The analysis of contact force provides both theoretical and experimental foundations for the design and application of vascular interventional robot guidance systems.
2 November 2022 in Frontiers in Materials
Purpose Acute massive pancreaticoduodenal artery (PDA) hemorrhage represents an urgent condition. Here, we report our experience in transcatheter arterial embolization (TAE) using N-butyl-2 cyanoacrylate (NBCA) Glubran® 2 for this condition. Methods A retrospective study of 10 consecutive patients (mean, 55.2 ± 15.9 years; range, 27–74 years) was conducted from April 2015 to April 2021. The data, including baseline characteristics, control of active PDA hemorrhage (the technical and clinical outcomes), volumes of Glubran 2, and related complications, were collected from medical archives. Technical success was defined as complete occlusion of bleeding vessels on the final arteriogram. Clinical success was defined as the sustained resolution of symptoms or signs of PDA hemorrhage without the need for repeat endovascular or surgical treatment after TAE. Safety was evaluated based on the occurrence of complications. Results Glubran 2 was empirically used for six patients (6/10) with PDA hemorrhage without pseudoaneurysm (PSA), and a combination of Glubran 2 and microcoils (n = 13) was used for four patients (4/10) with PSA. The concentration ratios were 1:2–1:4 mixtures of Glubran 2 and ethiodized oil, and the median total volume injected was 1.1 ml (range, 0.7–1.6 ml). Technical success based on 10 episodes of TAEs was 100% (10/10). Early rebleeding did not occur, and repeat TAE was not necessary. Clinical success was 100% (10/10). No nontarget embolization or embolization-related complications occurred. Two patients (2/10) experienced minor complications of postembolization syndrome. During a median follow-up time of 3 months, no recurrent hemorrhage was recorded. Conclusion Urgent TAE with the use of NBCA Glubran 2 plays an important role in controlling massive PDA hemorrhage. It is minimally invasive, effective, relatively safe, and likely to reduce the need for immediate traditional surgery. The condition with PSA may determine the microcoils employed.
9 September 2022 in Clinical and Applied Thrombosis/Hemostasis
Objective: This study investigates the safety and efficacy of endovascular treatments on pregnancy-related iliofemoral deep vein thrombosis (DVT). Methods: We retrospectively reviewed data of 46 patients who had symptomatic pregnancy-related iliofemoral DVT and underwent endovascular treatment. The patients treated with catheter-directed thrombolysis (CDT) were classified as the CDT group. In contrast, those treated with CDT combined with pharmacomechanical thrombectomy (PMT) or angioplasty/stenting were classified as the pharmacomechanical catheter-directed thrombolysis (PCDT) group. Results: Based on the immediate post-operative clot burden reduction rate analysis of 46 patients: 22 cases were completely dissolved (lysis grades III), 12 were partially dissolved (lysis grades II), and 12 failed (lysis grades I). There was a statistically significant difference in the rate of clot burden reduction between the CDT group (n = 19) and the PCDT group (n = 27) ( p = 0.001). There was no statistically significant difference in the number of bleeding events between the two groups ( p = 0.989). At 24 months, cumulative venous patency in the CDT group was 50.0%, compared to 78.2% in the PCDT group. Furthermore, there was a statistically significant difference in Villalta score (p = 0.001) and venous severity scoring (VCSS score) (p = 0.005) between the two groups. Conclusions: CDT treatment combined with PMT or angioplasty/stenting is comparatively safe and effective for pregnant-related DVT patients. PCDT outperforms CDT in terms of immediate efficacy and reduces the incidence of post-thrombotic syndrome with better midterm outcomes.